Drug developer Ra Pharmaceuticals is closing big tranches from big backers. The company just completed an $8.6 million second tranche in a $27.6 million Series A financing secured in February 2010. New Enterprise Associates is the lead investor, and Morgenthaler, Novartis Venture Funds and Amgen Ventures are also participating. Ra raised its first $10.33 million tranche in February, so the total raised to date is now $18.93 million. The company's Cyclomimetic drug discovery and development platform is for the treatment of hereditary angioedema (HAE), a rare and often fatal disorder of the immune system.